Page Title
Clinical Trial Finder
You can help advance cystic fibrosis research — starting now.
Tailor your search using the filters on the left.
Need help? Watch a video tutorial or contact the Clinical Trial Navigator, a real person who can assist you.
Showing 1-2 of 2 studies
Tailor your search using the filters on the left.
Need help? Watch a video tutorial or contact the Clinical Trial Navigator, a real person who can assist you.
Showing 1-2 of 2 studies
-
Anti-InflammatoryCompleted with Results
Phase 2 study of JBT-101 in people with CF , protocol number Corbus JBT101-CF-002This study evaluated the safety and effectiveness of the anti-inflammatory drug JBT-101 (lenabasum) in people with cystic fibrosis age 12 years and older.
-
Age:
12 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40 to 100%
-
Number of Visits:
10
-
Length of Participation:
32 weeks
-
-
Anti-InflammatoryCompleted with Results
Phase 2 study of JBT-101 in people with CF , protocol number Corbus JBT101-CF-001This study evaluated the safety and effectiveness of the anti-inflammatory drug JBT-101 (lenabasum), as well as how the body processes the drug, in adults with CF.
-
Age:
18 Years to 65 Years
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
8
-
Length of Participation:
127 days
-
Showing 1-2 of 2 studies
- 1
Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.
Related Topics
CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Learn MoreSign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More